Alexza begins Phase 2a study of AZ-002 for ARS-related epilepsy management Alexza Pharmaceuticals.

ARS happens in a subset of patients with epilepsy who regularly experience breakthrough seizures, despite treatment with a normal regimen of anti-epileptic medications. ‘We has been dealing with a few of the leading opinion leaders in neuro-scientific epilepsy to finalize our advancement technique for AZ-002,’ stated James V. Cassella, PhD, Executive Vice President, Research and Development, and Chief Scientific Officer of Alexza. ‘We think that AZ-002, if approved, could greatly benefit epilepsy patients who knowledge seizure emergencies like ARS.’ Dr.Jeffrey Ebersole, Biomedical research has a background of bipartisan support, today are a lot more than recouped and necessary for continued development because policymakers have long recognized that investments. The LA Times’ World Now blog writes, Rich countries saved money by schooling fewer doctors than they needed and making up the gap by importing medical personnel, according to the report .K. Writes, What’s needed is a ‘whole of government’ strategy in the developed globe, where aid activities, immigration plan, regulatory bodies, and domestic training of health professionals are better aligned .